Erythrocyte-binding therapeutics

Patent metadata

Field	Value
Publication number	US-10919963-B2
Application number	US-201916523877-A
Country	US
Kind code	B2
Filing date	Jul 26, 2019
Priority date	Aug 10, 2010
Publication date	Feb 16, 2021
Grant date	Feb 16, 2021

Abstract

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.

First claim

What is claimed is:

1. A composition for use in inducing tolerance comprising:
an antigen to which tolerance is desired;
wherein the antigen is selected from an immunogenic portion of myelin oligodendrocyte glycoprotein, myelin oligodendrocyte glycoprotein, and combinations thereof;

an erythrocyte-binding moiety,
wherein the erythrocyte-binding moiety has the ability to non-covalently, specifically bind an exterior erythrocyte surface in situ in blood,
wherein the erythrocyte-binding moiety comprises an antibody fragment directed against glycophorin A,

wherein the antigen to which tolerance is desired is recombinantly fused to the erythrocyte-binding moiety,
wherein, upon administration to a human in which tolerance to the antigen is desired:
the composition binds to CD45 negative cells, but not to CD45 positive cells, and the composition reduces, fails to induce, or prevents inflammatory responses in antigen-specific T cells as compared to when the human is exposed to the antigen alone.

2. The composition of claim 1 wherein the composition reduces the number of resident lymph node and spleen cells expressing interferon-gamma (IFNγ), as compared to the number of resident lymph node and spleen cells expressing IFNγ when the human is exposed to the antigen alone.

3. The composition of claim 1 wherein the erythrocyte-binding moiety is fused, optionally via a linker, to the N-terminus of the antigen.

4. The composition of claim 3 wherein the erythrocyte-binding moiety is derived from 10F7.

5. The composition of claim 1 wherein the erythrocyte-binding moiety is affinity matured.

6. The composition of claim 1 wherein the erythrocyte-binding moiety is derived from 10F7 and the antigen to which tolerance is desired is an immunogenic portion of myelin oligodendrocyte glycoprotein.

7. The composition of claim 6 wherein the administration of the composition ameliorates multiple sclerosis.

8. A composition comprising an antigen recombinantly fused or chemically conjugated with an erythrocyte-binding moiety;
wherein the erythrocyte-binding moiety comprises an antibody fragment or a peptide ligand that specifically binds to human erythrocytes; and
wherein the antigen is an antigen to which a subject develops an unwanted immune response,
wherein the antigen is associated with multiple sclerosis, and
wherein the composition reduces the number of resident lymph node and spleen cells expressing interferon-gamma (IFNγ), as compared to the number of resident lymph node and spleen cells expressing IFNγ when the human is exposed to the antigen alone.

9. The composition of claim 8 , wherein the peptide ligand comprises SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, or SEQ ID NO:17.

10. The composition of claim 8 , wherein the antigen comprises an immunogenic portion of myelin oligodendrocyte glycoprotein.

11. The composition of claim 10 , wherein the erythrocyte-binding moiety comprises an antibody fragment, wherein the antibody fragment comprises and affinity matured antibody fragment.

12. The composition of claim 11 wherein the erythrocyte-binding moiety is derived from 10F7.

13. The composition of claim 8 wherein the administration of the composition ameliorates multiple sclerosis.

14. A composition comprising an antigen recombinantly fused or chemically conjugated with an erythrocyte-binding moiety;
wherein the erythrocyte-binding moiety comprises an antibody, antibody fragment, or a single chain variable fragment (scFv) that binds to human glycophorin A; and
wherein the antigen is a self-antigen to which a subject develops an unwanted immune response, and
wherein the self-antigen is associated with multiple sclerosis.

15. The composition of claim 14 , wherein the self-antigen is selected from a portion of myelin basic protein, a portion of myelin oligodendrocyte glycoprotein, a portion of proteolipid protein, myelin basic protein, myelin oligodendrocyte glycoprotein, proteolipid protein, and combinations thereof.

16. The composition of claim 14 , wherein the erythrocyte-binding moiety is fused to the antigen via recombinant DNA technology.

17. The composition of claim 14 , wherein the erythrocyte-binding moiety is fused, optionally via a linker, to the N- or C-terminus of the antigen.

18. The composition of claim 14 , wherein the erythrocyte-binding moiety comprises an antibody fragment, and wherein the erythrocyte-binding moiety is derived from a 10F7 clone.

19. The composition of claim 14 , wherein the erythrocyte-binding moiety is an antibody fragment, wherein the antibody fragment is affinity matured, and wherein the antigen to which tolerance is desired comprises a portion of myelin basic protein.

20. The composition of claim 14 , wherein the erythrocyte-binding moiety is an antibody fragment, wherein the antibody fragment is affinity matured, and wherein the antigen to which tolerance is desired comprises an immunogenic portion of myelin oligodendrocyte glycoprotein.

Assignees

• Ecole Polytechnique Fed Lausanne Epfl

Inventors

• Hubbell Jeffrey A
• Kontos Stephan
• Dane Karen Y

Classifications

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2319/23

  containing a GST-tag · CPC title

• C07K16/30

  from tumour cells · CPC title

• C07K16/28 Primary

  against receptors, cell surface antigens or cell surface determinants · CPC title

• A61K2039/6031

  Proteins · CPC title